COVID-19疫苗接种后免疫性血小板减少症加重
73%无新发症状且血小板计数无显著下降;12%在接种后2-5天内血小板计数中位下降96%并出现新出血症状,经糖皮质激素±IVIG挽救治疗后血小板中位3天恢复至>30×10^9/L。ITP加重与缓解状态、合并ITP治疗或疫苗类型无关。
要点
- 12%慢性ITP患者接种后2-5天血小板中位下降96%并出现新出血症状
- 经糖皮质激素±IVIG治疗后血小板中位3天恢复至>30×10^9/L
- ITP加重与缓解状态、合并治疗或疫苗类型无关,第二剂安全性需谨慎评估
核心结论
- COVID-19疫苗接种后12%的慢性ITP患者出现血小板显著下降伴新出血症状,但经挽救治疗可恢复。
主要发现
- 73%患者无新发症状且血小板计数无显著下降。
- 12%患者接种后2-5天内血小板计数中位下降96%并出现新出血症状。
- 经糖皮质激素±IVIG挽救治疗后,血小板中位3天恢复至>30×10^9/L。
- ITP加重与缓解状态、合并ITP治疗或疫苗类型无关。
临床怎么用
- 对慢性ITP患者接种COVID-19疫苗后应监测血小板计数和出血症状,尤其接种后2-5天。
- 出现血小板显著下降伴出血时,可考虑糖皮质激素±IVIG挽救治疗。
- 第二剂疫苗接种的安全性需仔细评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There is concern that COVID-19 vaccination may adversely affect immune thrombocytopenia (ITP) patients. Fifty-two consecutive chronic ITP patients were prospectively followed after COVID-19 vaccination. Fifteen percent had no worsening of clinical symptoms but no post-vaccination platelet count; 73% had no new symptoms and no significant platelet count decline. However, 12% had a median platelet count drop of 96% within 2-5 days post vaccination with new bleeding symptoms; after rescue therapy with corticosteroids +/- intravenous immunoglobulin (IVIG), platelets recovered to >30 × 109 /l a median three days later. ITP exacerbation occurred independently of remission status, concurrent ITP treatment, or vaccine type. Safety of a second vaccine dose needs careful assessment.
引用
- Kuter DJ. Exacerbation of immune thrombocytopenia following COVID-19 vaccination. Br J Haematol. 2021. PMID: 34075578. doi:10.1111/bjh.17645
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。